Section
The ALTER-L043 trial reveals that combining penpulimab, anlotinib, and chemotherapy achieves a staggering 76% major pathologic response rate in resectable non-small cell lung cancer, signaling a potential shift in neoadjuvant treatment para
Extended follow-up of the NEOpredict-Lung trial demonstrates that short-course preoperative nivolumab, with or without relatlimab, yields high 3-year survival rates and significant nodal downstaging in resectable NSCLC, positioning dual che
The international PROTHOR trial reveals that using higher PEEP and recruitment manoeuvres during one-lung ventilation does not decrease postoperative pulmonary complications compared to a lower PEEP strategy, while notably increasing intrao
A prospective multicenter study demonstrates that using a single clinical question—whether pulmonary embolism is the most likely diagnosis—to adjust D-dimer thresholds can safely reduce chest imaging by 19% in emergency departments without
The Phase 2 Evolution trial suggests that for unresectable, locally advanced NSCLC with PD-L1 TPS ≥50%, a radiotherapy-free regimen of pembrolizumab plus chemotherapy is feasible, yielding a 67% 2-year progression-free survival rate and a m
The Phase 2a ENV-IPF-101 trial demonstrates that taladegib, a Hedgehog pathway inhibitor, not only stabilizes but may improve forced vital capacity and reduce fibrotic burden in patients with idiopathic pulmonary fibrosis over 12 weeks.
The Phase 2b PanACEA-DECODE-01 trial identifies delpazolid 1200 mg once daily as an effective and safer oxazolidinone alternative to linezolid, demonstrating a 38% faster mycobacterial load decline when added to a bedaquiline, delamanid, an
The Phase 2b PanACEA-SUDOCU-01 trial demonstrates that sutezolid significantly increases the bactericidal activity of a bedaquiline-delamanid-moxifloxacin regimen in pulmonary tuberculosis, notably without the neuropathy or myelosuppression
This article synthesizes recent findings on the KRAS G12V mutation in non-small cell lung cancer, highlighting its unique molecular profile, strong association with smoking, and superior response to immunotherapy compared to traditional che
This phase 1 trial identifies APG-2449 as a potent ALK/ROS1/FAK inhibitor. It shows significant efficacy in TKI-naïve and second-generation TKI-resistant ALK+ NSCLC, with high blood-brain barrier penetration and a manageable safety profile,
The final analysis of the Phase III ALEX trial confirms alectinib’s superior long-term efficacy over crizotinib, achieving a median overall survival of 81.1 months and significant intracranial benefits, solidifying its role as the fir
A landmark study of over 18,000 patients reveals that sarcoidosis incidence and prevalence in England are rising, particularly among older adults. With a 36% higher mortality risk compared to the general population, these findings demand a
This review synthesizes the findings of the PROVID randomized clinical trial and broader literature, demonstrating that awake prone positioning (APP) significantly reduces the probability of intubation and death in patients with COVID-19 hy
A massive cohort study of 11.3 million US veterans reveals that obstructive sleep apnea is an independent risk factor for Parkinson disease, but early treatment with CPAP significantly reduces this risk, particularly in women.
This review analyzes the long-term effectiveness of RSV vaccination among US Veterans, revealing significant protection against severe outcomes that wanes over two seasons, particularly in immunocompromised populations.
Recent evidence reveals that COPD in adults under 50 is more prevalent than previously thought, significantly increasing the risk of premature death and heart failure. Furthermore, impaired lung function trajectories starting in childhood p
The MULTI-CAP trial demonstrated that combining multiplex PCR and procalcitonin did not significantly increase the number of antibiotic-free days by Day 28 in ICU patients with pneumonia, although it did successfully reduce the cumulative d
The OPTIC-2 phase 3b trial confirms that omadacycline is noninferior to moxifloxacin for treating community-acquired bacterial pneumonia (CABP). This once-daily aminomethylcycline offers a robust IV-to-oral monotherapy option with a favorab
A reanalysis of the ICAR trial reveals that ARDS inflammatory subphenotypes remain remarkably stable over 28 days. The hyperinflammatory profile is linked to higher mortality and distinct biomarkers, with Bayesian modeling showing minimal t
A groundbreaking study utilizing an AI classifier demonstrates that ARDS inflammatory phenotypes are dynamic and dictate corticosteroid efficacy. While hyperinflammatory patients benefit from steroids, hypoinflammatory patients face increas
